Abstract
Effective response to vaccination requires activation of the innate immune system, triggering the synthesis of inflammatory cytokines. The subjective symptoms related to this, referred to as reactogenicity, affect a variable percentage of vaccinated people to different degrees, with evidence supporting a relationship between the severity of symptoms a person experiences and their eventual immune response. Wearable sensors allow for the identification of objective evidence of physiologic changes a person experiences in response to vaccine-induced inflammation, but as these changes are subtle, they can only be detected when an individual’s pre-vaccination normal variability is considered. We used a wearable torso sensor patch and a machine learning method of similarity-based modeling (SBM), which learns the dynamic interplay between multivariate input sources, to create a physiologic digital twin for 88 people receiving 104 vaccine doses. By effectively removing expected variations and leaving only vaccine-induced differences, we developed a multivariate digital biomarker that incorporates changes in multiple continuously monitored physiologic data streams to measure the degree and duration of vaccine induced inflammation. This objective measure correlated with subjective symptoms, and in a 20-person subset, both humoral and cellular immunogenicity.
Competing Interest Statement
The current study was sponsored by physIQ, Inc. (Chicago, IL, USA) a company that has since been purchased by Prolaio, Inc. (Scottsdale, AZ, USA). A patent was filed by physIQ for the digital biomarker described. Some co-authors are employees of the company (JS, MG, SW) or a paid consultant (SRS). HG and EP are employees of CellCarta Bioscience, Inc. (Montreal, QC, Canada).
Funding Statement
The study was funded by physIQ, Inc. (Chicago, IL, USA) a company that has since been purchased by Prolaio, Inc. (Scottsdale, AZ, USA). Some co-authors are employees of the company (JS, MG, SW) or a paid consultant (SRS).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The manuscript contains data from two near-identical prospective studies. The Sterling IRB gave ethical approval for the VIII study. The IRB of Purdue University gave ethical approval for the COmMON SENS study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The data obtained in the study is the property of the sponsor. Data sharing can be determined on a per case basis via request to authors.
